Despite a superior revenue outlook, the company isn't trading at a higher P/S due to potential risks like not meeting analysts' revenue projections in tough industry conditions. Investors anticipate future revenue volatility.
Bio-Rad's unstable profits and stale growth over the past three years are worrying. Despite a rise in stocks, long-term performance lacks strength. If fundamentals signal sustainable growth, the current sell-off could be a chance.
バイオ ラッド ラボラトリーズ Aに関するコメント
まだコメントはありません